

ICMJE DISCLOSURE FORM

Date: 7/7/2026

Your Name: Sharon Batt

Manuscript Title: From blots to a spreading stain on Alzheimer's research...and beyond?

Manuscript Number (if known): 1315

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. ☒ None	Click the tab key to add additional rows.
Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above). ☐ None	Contract with PharmedOut (Georgetown University, Washington DC) for research and writing of the paper <i>What Needs to Change at the FDA? Protecting and Advancing Public Health</i>, which includes discussion of the FDA's recent approval of Alzheimer's drugs.] Funding for the research project on the FDA was paid to PharmedOut by Arnold Ventures. Payments to me as primary researcher and writer received from PharmedOut in 2023, 2024 and 2025. Disparities in access to precision oncology drugs across Canada, grant awarded to Queen's University by the Terry Fox Research Institute. Co-investigator. Oct. 2024-present. Payment of \$500 from Queen's University for contribution providing patient-survivor perspective in grant preparation and research process.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1" style="width: 100%;"> <tr> <td>Payment for chapter contributions to a book on advocacy and women's health (manuscript currently in progress).]</td> <td>Payment in 2026 from PharmedOut.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Payment for chapter contributions to a book on advocacy and women's health (manuscript currently in progress).]	Payment in 2026 from PharmedOut.						
Payment for chapter contributions to a book on advocacy and women's health (manuscript currently in progress).]	Payment in 2026 from PharmedOut.										
6	Payment for expert testimony	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☐ None <table border="1" style="width: 100%;"> <tr> <td>Support to attend the 2026 AGM of the American Association of Cancer Research (AACR26) in April 2026, provided by the Canadian Institute for Health Research (CIHR). Cost of printing a poster, "More drugs, but are they good drugs?" paid by Common Sense Oncology].</td> <td>Funding for my travel, food, hotel, paid to AACR by CIHR. Poster cost (approx. Can \$120) reimbursed to me.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Support to attend the 2026 AGM of the American Association of Cancer Research (AACR26) in April 2026, provided by the Canadian Institute for Health Research (CIHR). Cost of printing a poster, "More drugs, but are they good drugs?" paid by Common Sense Oncology].	Funding for my travel, food, hotel, paid to AACR by CIHR. Poster cost (approx. Can \$120) reimbursed to me.						
Support to attend the 2026 AGM of the American Association of Cancer Research (AACR26) in April 2026, provided by the Canadian Institute for Health Research (CIHR). Cost of printing a poster, "More drugs, but are they good drugs?" paid by Common Sense Oncology].	Funding for my travel, food, hotel, paid to AACR by CIHR. Poster cost (approx. Can \$120) reimbursed to me.										
8	Patents planned, issued or pending	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	☐ None <table border="1" style="width: 100%;"> <tr> <td>Committee Member, Revision of Faculty of Medicine Industry Relations Guidelines, Dalhousie University, August 2025-March 2026.</td> <td>Unpaid</td> </tr> </table>		Committee Member, Revision of Faculty of Medicine Industry Relations Guidelines, Dalhousie University, August 2025-March 2026.	Unpaid						
Committee Member, Revision of Faculty of Medicine Industry Relations Guidelines, Dalhousie University, August 2025-March 2026.	Unpaid										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Representing the Dalhousie Department of Bioethics.]	
		Scientific Advisory Committee on Health Products for Women, Health Canada, Core committee member (January 2019-July 2024).	Unpaid.
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☐ None	
		Nova Scotia Health Coalition, board member (2018; 2023-2025); executive board member (2019-2020), Secretary (2020-2023).]	
		I am a co-chair of Independent Voices for Safe and Effective Drugs, a non-profit pan-Canadian organization, (ivsed.org). In August 2023 IVSED published a blog entitled "New Alzheimer's Drugs but Same Old Hype" by IVSED member Linda Furlini. I made minor editing suggestions to the article prior to posting.	All work at IVSED is unpaid.
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	
Please place an "X" next to the following statement to indicate your agreement: ☐ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			